GlaxoSmithKline (GSK) is giving Renaissance Acquisition Holdings, a RoundTable Healthcare Partners portfolio company, the rights in the U.S. to manufacture, market, and sell six of its dermatology products and three of its antiviral products. These products include:
- Evoclin® (clindamycin phosphate) foam, 1%
- Extina® (ketoconazole) foam, 2%
- Luxiq® (betamethasone valerate) foam, 0.12%
- Olux® (clobetasol propionate) foam, 0.05%
- Olux-E® (clobetasol propionate) foam, 0.05%
- Vusion® (miconazole nitrate 0.25%, zinc oxide 15%, and white petrolatum 81.35%) ointment
- Zovirax® (acyclovir) capsules
- Zovirax® (acyclovir) tablets
- Zovirax® (acyclovir) suspension
The products from GSK and Stiefel, a company acquired by GSK in April 2009, will be marketed through Renaissance’s branded division Prestium Pharma.
“This agreement allows U.S. patients to continue to have access to treatments they value and allows the Stiefel U.S. team to focus on growth and development of new treatments within our core dermatology portfolio,” said Stiefel president Simon Jose.
While GSK is unloading these dermatology and antiviral products, the firm is picking up more at the same time: Just yesterday, it entered an agreement with MorphoSys to develop and commercialize MOR103, MorphoSys’ HuCAL-derived antibody against GM-CSF, which is in development for mild to moderate rheumatoid arthritis.